Why Is Micro Cap HeartBeam Stock Surging On Wednesday?

Core Insights - HeartBeam, Inc. has received FDA 510(k) clearance for its 12-lead ECG synthesis software, enabling at-home assessment of arrhythmias [1][2] - The stock price has surged by 75.73% to $1.42 following the announcement [7] Group 1: FDA Clearance and Technology - The FDA clearance follows HeartBeam's successful appeal against a previous Not Substantially Equivalent determination [2] - HeartBeam's technology captures heart electrical signals in three dimensions, providing a comprehensive 12-lead ECG representation [2] Group 2: Growth Initiatives - The company plans a limited launch in early 2026 targeting select concierge and preventive cardiology practices to validate real-world performance [3][7] - HeartBeam aims to pursue an additional indication for heart attack detection, potentially reaching tens of millions of U.S. patients [4] Group 3: Product Development - The company is developing an extended-wear 12-lead ECG patch, currently at the working-prototype stage, targeting a multi-billion-dollar reimbursable market [5] - HeartBeam intends to leverage longitudinal data from its 3D ECG technology for AI-driven screening and predictive tools [6]